Dr Zonder on the Expansion of Targeted Therapies in R/R Multiple Myeloma
Jeffery Zonder, MD, discusses the need for expanding the armamentarium of targeted therapies for patients with relapsed/refractory multiple myeloma.
Related Articles
Additive IL-6 Inhibition Improves ICI-Related Response Rates and Safety in Advanced Melanoma
Janice Mehnert, MD, discusses the rationale for adding IL-6 inhibition to an ICI backbone and data with sarilumab plus ICIs in advanced melanoma.
IMproveMF Trial Shows Early Potential of Imetelstat Plus Ruxolitinib in Myelofibrosis
John Mascarenhas, MD, discusses early findings from the IMproveMF trial combining imetelstat with ruxolitinib in intermediate- to high-risk myelofibrosis.
Subgroup Analysis Supports Encorafenib Plus Cetuximab/mFOLFOX6 as New SOC for BRAF V600E+ mCRC
Post hoc analyses compared encorafenib plus cetuximab and mFOLFOX6 with different BREAKWATER control arm regimens.
Survival Benefit, Neutropenia Risk Influence Third-Line Treatment Preferences for mCRC in Germany and the UK
A survey of UK and German physicians found that OS gains were needed to accept increased toxicities or treatment burden with third-line regimens in mCRC.
An Oncology Fellow Reflects on End-of-Life Patient Care
Rebecca Zweifler, MD, pens a personal essay reflecting on her experience with a patient who left a lasting impact on her.
On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC
TACE plus atezolizumab and bevacizumab may represent effective option for untreated intermediate-to-high tumor burden unresectable HCC.
Fruquintinib Demonstrates Clinical Benefit in mCRC Irrespective of Metastatic Sites at Baseline
A post hoc subgroup analysis of FRESCO-2 shed light on the safety and efficacy of fruquintinib by metastatic site in metastatic colorectal cancer.
Attention to Detail and Patience Are Key in the Job Search Process as Oncology Fellows
An assistant professor at The Warren Alpert Medical School of Brown University discusses offers insights on the job search process following fellowship.
Perioperative Durvalumab/FLOT Does Not Diminish PROs in Resectable Gastric/GEJ Adenocarcinoma
Durvalumab plus FLOT did not lead to differences in patient-reported outcomes vs placebo plus FLOT in resectable gastric/GEJ cancer.
A Patient-Centered Approach: Treatment Strategies for Progression and Intolerance in R/R CLL
Catherine Coombs; John Allan, MD, and Joanna Rhodes, MD, MSCE, discuss how to manage chronic lymphocytic leukemia (CLL) patients who develop high-risk disease features at…